Login
Companies $ASH
$75.57 +$0.00 (0.0%) After hours
ASHLAND INC. logo

ASHLAND INC.

ashland.com

What Do They Do?

Sells specialty ingredients and additives to pharmaceutical, branded consumer-products, and industrial customers.

How Do They Make Money?

Ashland sells goods under contracts or purchase orders and generally collects payment after delivery.

revenue
SegmentShareRevenue
Life Sciences
Sold outright

35%
FY2022: 34%
Personal Care
Sold outright

32%
FY2022: 28%
Specialty Additives
Sold outright

28%
FY2022: 30%
Intermediates
Sold outright
7.5%
FY2022: 11%

Who Are Their Customers?

Ashland serves pharmaceutical, food and beverage manufacturers, branded consumer-product formulators, and industrial customers in coatings, construction and other markets. It markets and distributes its products across the Americas, Europe, the Middle East, Africa and Asia Pacific.

Do Revenues Turn Into Profits?

No. It lost $845M in FY2025.

Operating income, FY2025
−42% of revenue
▼ −2881% (Loss) vs FY2024 (−$26M, −1%)
Net income, FY2025
−46% of revenue
▼ Turned to a loss vs FY2024 ($169M, 8%)
Free cash flow, FY2025
0% of revenue
▼ Turned to a loss vs FY2024 ($274M, 13%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Jun 30, 2026
Revenue
▲ +7%
vs $463M in Q3 FY2025
Net income
▲ Turned profitable
vs −$742M in Q3 FY2025
Life Sciences share of revenue vs 35.0% in Q3 FY2025
  • Jul 28, 2026 Ashland reaffirmed full-year sales and Adjusted EBITDA guidance Ashland reaffirmed sales guidance of $1,835-$1,870 million and Adjusted EBITDA guidance of $385-$400 million.
  • Apr 28, 2026 Ashland updated its full-year sales and Adjusted EBITDA outlook It set sales guidance at $1,835-$1,870 million and Adjusted EBITDA guidance at $385-$400 million, citing a slower productivity ramp at Hopewell.
  • Feb 2, 2026 Ashland narrowed full-year Adjusted EBITDA guidance The range was $400-$420 million, reflecting temporary effects from the Calvert City startup delay and weather disruptions.

Shrinking. Revenue fell 14% in 4 years, from $2.1B in FY2021 to $1.8B in FY2025, about 4% a year.

Nutraceuticals sale Life Sciences no longer includes Ashland’s nutraceuticals business: the older report described nutraceutical products and related formulation, particle-engineering and contract-manufacturing services, while the latest report says the business was sold.

Revenue over time
Life Sciences Personal Care Specialty Additives Intermediates
$2.5B$1.3B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support